论文部分内容阅读
目的 研究东菱克栓酶 (Batroxobin)治疗急性进展型脑梗死的临床效果及其安全性。方法 5 5例急性颈内动脉系统进展型脑梗死患者随机分为治疗组和对照组。 2组均以低分子右旋糖酐静脉滴注作为基础治疗。治疗组加用东菱克栓酶静脉滴注 ,首剂量为 10BU ,以后隔日给予 5BU ,共 2 5BU ;对照组加用盐酸川芎嗪注射液静脉滴注。结果 治疗组患者终止病情继续进展的时间明显早于对照组。从治疗后第 3天开始 ,治疗组临床神经功能缺损评分 (neuro functiondeficitscore ,NFD)明显优于对照组 (P =0 .0 44 ) ,至治疗后第14天 ,两组NFD评分相差更显著 (P =0 .0 0 1)。治疗组血纤维蛋白原水平降低显著 ,不良反应轻微。结论 东菱克栓酶可比较迅速地终止急性进展型脑梗死患者的病情进展 ,明显加快其神经功能的康复 ,而且治疗时间窗宽广 ,安全性良好。
Objective To study the clinical efficacy and safety of Batroxobin in the treatment of acute progressive cerebral infarction. Methods Fifty-five patients with acute internal carotid artery progressive cerebral infarction were randomly divided into treatment group and control group. 2 groups were low molecular dextran intravenous infusion as the basis for treatment. In the treatment group, Batroxobin was intravenously instilled at the first dose of 10BU, followed by 5BU every other day for a total of 2 5BU. The control group was given intravenous injection of ligustrazine hydrochloride injection. Results The treatment group patients terminated the disease progression significantly earlier than the control group. From the third day after treatment, the clinical neurological deficit score (NFD) of the treatment group was significantly better than that of the control group (P = 0.044). On the 14th day after treatment, the NFD scores of the two groups were significantly different P = 0 .0 0 1). Treatment group fibrinogen levels decreased significantly, mild adverse reactions. Conclusion Batroxobin can terminate the progression of patients with acute progressive cerebral infarction more rapidly and significantly speed up the recovery of neurological function. Moreover, the therapeutic time window is wide and the safety is good.